TrialPath

3 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Heart / cardiovascular diseaseKidney disease

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Crohn's / ulcerative colitis (IBD)

    📍 Brigham and Women's Hospital · Chestnut Hill, MA · +1 more US site · Get directions →

    This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis. Patients who qualify are adults who have not responded to treatments for their severe ulcerative colitis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Crohn's / ulcerative colitis (IBD)

    📍 Brigham and Women's Hospital · Chestnut Hill, MA · Get directions →

    This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with active mild ulcerative colitis. Participation in this study will take 12 weeks long and the study is structured as a crossover study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication.

    ✓ Study care freePhase 2Ages 18–75Learn more →